Evidence map›Paper›PMID 37154727›Full record

ArticleMicrobiology spectrum2023

Efficient SARS-CoV-2 Surveillance during the Pandemic-Endemic Transition Using PCR-Based Genotyping Assays.

Lianne Koets, Karin van Leeuwen, Maaike Derlagen, Jalenka van Wijk, Nadia Keijzer, Jelena D M Feenstra, Manoj Gandhi, Oceane Sorel, Thijs J W van de Laar, Marco H G M Koppelman

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Lianne KoetsSanquin Research and Lab Services, National Screening Laboratory of Sanquin, Amsterdam, The Netherlands.ORCID 0000-0002-2845-5694
Karin van LeeuwenSanquin Diagnostics, Department of Phagocytes Diagnostics, Amsterdam, The Netherlands.
Maaike DerlagenSanquin Diagnostics, Department of Immune Cytology, Amsterdam, The Netherlands.
Jalenka van WijkSanquin Diagnostics, Department of Immune Cytology, Amsterdam, The Netherlands.
Nadia KeijzerSanquin Diagnostics, Department of Immune Cytology, Amsterdam, The Netherlands.
Jelena D M FeenstraThermo Fisher Scientific, South San Francisco, California, USA.
Manoj GandhiThermo Fisher Scientific, South San Francisco, California, USA.
Oceane SorelThermo Fisher Scientific, South San Francisco, California, USA.
Thijs J W van de LaarSanquin Research, Department of Blood-Borne Infections, Amsterdam, The Netherlands.
Marco H G M KoppelmanSanquin Research and Lab Services, National Screening Laboratory of Sanquin, Amsterdam, The Netherlands.
Sanquin · NLThermo Fisher Scientific (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants of concern (VOC) pose an increased risk to public health due to higher transmissibility and/or immune escape. In this study, we assessed the performance of a custom TaqMan SARS-CoV-2 mutation panel consisting of 10 selected real-time PCR (RT-PCR) genotyping assays compared to whole-genome sequencing (WGS) for identification of 5 VOC circulating in The Netherlands. SARS-CoV-2 positive samples (N = 664), collected during routine PCR screening (15 ≤

Indexed as

COVID-19PandemicsCOVID-19 TestingGenotypeHumansMutationReal-Time Polymerase Chain ReactionSARS-CoV-2RT-PCR genotyping assaysSARS-CoV-2variant of concern

Identifiers

PMID37154727
PMCPMC10269661
OpenAlexW4375860075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.